drugset
Drugs / GSK679586
last change Jan 2013 re-read 2 minutes ago

GSK679586

Monoclonal antibody targets IL13

Developed for
asthma
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

today NCT00843193 · Ph 2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00843193 Dec 2008 → Jul 2010 asthma GlaxoSmithKline Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00411814 Comparator Nov 2006 → Feb 2008 asthma GlaxoSmithKline Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as GSK679586 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00843193 ↗
1

NCT00411814 ↗
Modality Monoclonal antibody “a novel humanized anti-IL-13 IgG1 monoclonal antibody” PMID 22616628 ↗ Jan 2013
Route Intravenous “single intravenous infusions of GSK679586” PMID 22616628 ↗ Jan 2013
Target IL13 “anti-IL-13 monoclonal antibody” PMID 22616628 ↗ Jan 2013